David Church

Professor

Cancer Research UK Senior Cancer Research Fellow
Honorary Consultant in Medical Oncology

Research focus

We study the mechanisms underpinning the growth and suppression of bowel and womb cancers, focusing particularly on the immune response tumours induce and evade. We aim to identify new biomarkers and targets to better prevent and treat these common diseases

Key publications

Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study.

Wagner SJ. et al, (2023), Cancer cell, 41, 1650 - 1661.e4

Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis

Colling R. et al, (2015), Journal of Clinical Pathology, 68, 1036 - 1039

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

van Gool IC. et al, (2015), Clinical Cancer Research, 21, 3347 - 3355

Recent publications

Data from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

Blanc-Durand F. et al, (2026)

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

Blanc-Durand F. et al, (2026), Clinical Cancer Research, 32, 963 - 969

Supplementary Table S1 from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial